{
  "id": "han2012_jco",
  "name": "Han 2012 D2 Gastrectomy Survival Nomogram",
  "citation": "Han DS, et al. J Clin Oncol. 2012;30(31):3834-3840. DOI: 10.1200/JCO.2012.41.8343",
  "model_type": "cox",
  "outcome": "overall_survival",
  "description": "Cox proportional hazards model predicting 5- and 10-year overall survival after D2 gastrectomy for gastric cancer. Based on 7,954 patients from Seoul National University Hospital.",
  "timepoints": [5, 10],
  "baseline_survival": {
    "note": "Baseline survival S₀(t) not reported in original publication. Values calibrated to reproduce published cohort mean 5-year survival of 78.4% (Han et al., 2012, Figure 3). These are educational approximations requiring institutional validation.",
    "5_year_estimate": 0.52,
    "10_year_estimate": 0.43,
    "calibration_source": "Adjusted to match published cohort-level survival (78.4% at 5 years)",
    "validation_status": "Uncalibrated - requires institutional recalibration before clinical use",
    "calibration_needed": true,
    "calibration_method": "Empirical adjustment to match Han et al. 2012 Figure 3 cohort survival"
  },
  "variables": {
    "age": {
      "type": "categorical",
      "reference": "< 40",
      "unit": "years",
      "categories": {
        "< 40": 0.0000,
        "40-49": -0.1393,
        "50-59": 0.0862,
        "60-69": 0.4319,
        ">= 70": 0.8154
      },
      "description": "Age at diagnosis in predefined categories"
    },
    "sex": {
      "type": "categorical",
      "reference": "male",
      "categories": {
        "male": 0.0000,
        "female": -0.2231
      },
      "description": "Patient sex (female has protective effect)"
    },
    "location": {
      "type": "categorical",
      "reference": "upper",
      "categories": {
        "upper": 0.0000,
        "middle": -0.1863,
        "lower": -0.2877
      },
      "description": "Tumor location in stomach (upper/middle/lower third)"
    },
    "depth_of_invasion": {
      "type": "categorical",
      "reference": "mucosa",
      "categories": {
        "mucosa": 0.0000,
        "submucosa": 0.2311,
        "proper_muscle": 0.4637,
        "subserosa": 0.9933,
        "serosa": 1.2090,
        "adjacent_organ_invasion": 1.9895
      },
      "description": "T stage / depth of tumor invasion",
      "mapping": {
        "T1a": "mucosa",
        "T1b": "submucosa",
        "T2": "proper_muscle",
        "T3": "subserosa",
        "T4a": "serosa",
        "T4b": "adjacent_organ_invasion"
      }
    },
    "metastatic_lymph_nodes": {
      "type": "categorical",
      "reference": "0",
      "unit": "count",
      "categories": {
        "0": 0.0000,
        "1-2": 0.2546,
        "3-6": 0.7178,
        "7-15": 1.1787,
        ">= 16": 1.7281
      },
      "description": "Number of metastatic (positive) lymph nodes"
    },
    "examined_lymph_nodes": {
      "type": "continuous",
      "coefficient": -0.0943,
      "unit": "count",
      "description": "Number of examined lymph nodes (protective factor: more examined = better prognosis)",
      "clinical_note": "Coefficient is per node. Model assumes ≥15 nodes examined (inclusion criteria)"
    }
  },
  "inclusion_criteria": {
    "min_examined_nodes": 15,
    "surgery_type": "D2 lymphadenectomy",
    "resection_status": "R0 (complete resection)",
    "notes": "Model derived from patients who underwent D2 gastrectomy between 1986-2007"
  },
  "performance": {
    "c_index_internal": 0.78,
    "c_index_external": 0.79,
    "calibration": "Within 10% margin in both validation cohorts",
    "superiority": "Outperforms AJCC TNM 7th edition (0.78 vs 0.69, p<0.001)"
  },
  "validation": {
    "internal": "2,654 patients (SNUH)",
    "external": "2,500 patients (Cancer Institute Ariake Hospital, Tokyo, Japan)"
  },
  "limitations": [
    "Baseline survival S0(t) not explicitly provided in paper",
    "Model assumes Eastern population (Korean/Japanese)",
    "Not recalibrated for Western populations",
    "Does not account for adjuvant chemotherapy",
    "Educational implementation - requires institutional validation for clinical use"
  ]
}
